S&P 500   4,292.45 (+0.20%)
DOW   33,589.25 (+0.05%)
QQQ   355.17 (+0.09%)
AAPL   178.86 (-0.20%)
MSFT   332.50 (-0.35%)
META   270.45 (-0.25%)
GOOGL   127.12 (-0.15%)
AMZN   126.73 (+0.09%)
TSLA   228.20 (+3.11%)
NVDA   387.62 (+0.28%)
NIO   7.79 (-1.14%)
BABA   85.99 (-0.82%)
AMD   124.49 (+0.21%)
T   15.69 (+0.13%)
F   12.99 (+0.46%)
MU   69.47 (+2.86%)
CGC   0.76 (+3.16%)
GE   106.53 (+1.01%)
DIS   92.55 (+0.42%)
AMC   4.78 (+3.02%)
PFE   38.37 (-0.72%)
PYPL   65.29 (+0.42%)
NFLX   412.56 (+3.32%)
S&P 500   4,292.45 (+0.20%)
DOW   33,589.25 (+0.05%)
QQQ   355.17 (+0.09%)
AAPL   178.86 (-0.20%)
MSFT   332.50 (-0.35%)
META   270.45 (-0.25%)
GOOGL   127.12 (-0.15%)
AMZN   126.73 (+0.09%)
TSLA   228.20 (+3.11%)
NVDA   387.62 (+0.28%)
NIO   7.79 (-1.14%)
BABA   85.99 (-0.82%)
AMD   124.49 (+0.21%)
T   15.69 (+0.13%)
F   12.99 (+0.46%)
MU   69.47 (+2.86%)
CGC   0.76 (+3.16%)
GE   106.53 (+1.01%)
DIS   92.55 (+0.42%)
AMC   4.78 (+3.02%)
PFE   38.37 (-0.72%)
PYPL   65.29 (+0.42%)
NFLX   412.56 (+3.32%)
S&P 500   4,292.45 (+0.20%)
DOW   33,589.25 (+0.05%)
QQQ   355.17 (+0.09%)
AAPL   178.86 (-0.20%)
MSFT   332.50 (-0.35%)
META   270.45 (-0.25%)
GOOGL   127.12 (-0.15%)
AMZN   126.73 (+0.09%)
TSLA   228.20 (+3.11%)
NVDA   387.62 (+0.28%)
NIO   7.79 (-1.14%)
BABA   85.99 (-0.82%)
AMD   124.49 (+0.21%)
T   15.69 (+0.13%)
F   12.99 (+0.46%)
MU   69.47 (+2.86%)
CGC   0.76 (+3.16%)
GE   106.53 (+1.01%)
DIS   92.55 (+0.42%)
AMC   4.78 (+3.02%)
PFE   38.37 (-0.72%)
PYPL   65.29 (+0.42%)
NFLX   412.56 (+3.32%)
S&P 500   4,292.45 (+0.20%)
DOW   33,589.25 (+0.05%)
QQQ   355.17 (+0.09%)
AAPL   178.86 (-0.20%)
MSFT   332.50 (-0.35%)
META   270.45 (-0.25%)
GOOGL   127.12 (-0.15%)
AMZN   126.73 (+0.09%)
TSLA   228.20 (+3.11%)
NVDA   387.62 (+0.28%)
NIO   7.79 (-1.14%)
BABA   85.99 (-0.82%)
AMD   124.49 (+0.21%)
T   15.69 (+0.13%)
F   12.99 (+0.46%)
MU   69.47 (+2.86%)
CGC   0.76 (+3.16%)
GE   106.53 (+1.01%)
DIS   92.55 (+0.42%)
AMC   4.78 (+3.02%)
PFE   38.37 (-0.72%)
PYPL   65.29 (+0.42%)
NFLX   412.56 (+3.32%)
NASDAQ:ZVRA

Zevra Therapeutics (ZVRA) Stock Forecast, Price & News

$5.40
-0.03 (-0.55%)
(As of 09:02 AM ET)
Compare
Today's Range
$5.40
$5.40
50-Day Range
$4.23
$6.29
52-Week Range
$4.03
$6.92
Volume
7,730 shs
Average Volume
231,863 shs
Market Capitalization
$186.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Zevra Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
121.0% Upside
$12.00 Price Target
Short Interest
Bearish
6.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.06mentions of Zevra Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$178,055 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.47) to ($0.79) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

727th out of 982 stocks

Pharmaceutical Preparations Industry

354th out of 474 stocks


ZVRA stock logo

About Zevra Therapeutics (NASDAQ:ZVRA) Stock

Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Receive ZVRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ZVRA Stock News Headlines

The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
Q1 2023 Zevra Therapeutics Inc Earnings Call
Zevra Therapeutics: Q1 Earnings Snapshot
The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
ZVRA Zevra Therapeutics, Inc.
Zevra Therapeutics Inc (ZVRA)
Zevra Therapeutics (ZVRA) & Its Peers Head-To-Head Survey
Zevra Therapeutics Inc.
See More Headlines

ZVRA Price History

ZVRA Company Calendar

Last Earnings
5/15/2023
Today
6/07/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZVRA
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+121.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-41,540,000.00
Net Margins
-548.93%
Pretax Margin
-558.38%

Debt

Sales & Book Value

Annual Sales
$10.46 million
Book Value
$2.49 per share

Miscellaneous

Free Float
34,160,000
Market Cap
$187.55 million
Optionable
Optionable
Beta
2.19

Key Executives

  • Richard W. Pascoe
    Chief Executive Officer & Director
  • R. LaDuane Clifton
    Chief Financial Officer, Secretary & Treasurer
  • Sven Guenther
    Chief Scientific Officer
  • Daniel Gallo
    Senior Vice President-Medical Affairs & Advocacy
  • Timothy J. Sangiovanni
    Vice President & Controller













ZVRA Stock - Frequently Asked Questions

Should I buy or sell Zevra Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zevra Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ZVRA shares.
View ZVRA analyst ratings
or view top-rated stocks.

What is Zevra Therapeutics' stock price forecast for 2023?

1 Wall Street research analysts have issued twelve-month target prices for Zevra Therapeutics' stock. Their ZVRA share price forecasts range from $12.00 to $12.00. On average, they anticipate the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 121.0% from the stock's current price.
View analysts price targets for ZVRA
or view top-rated stocks among Wall Street analysts.

How have ZVRA shares performed in 2023?

Zevra Therapeutics' stock was trading at $5.39 at the start of the year. Since then, ZVRA shares have increased by 0.7% and is now trading at $5.43.
View the best growth stocks for 2023 here
.

When is Zevra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ZVRA earnings forecast
.

How were Zevra Therapeutics' earnings last quarter?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) issued its quarterly earnings data on Monday, May, 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.08. The business had revenue of $2.88 million for the quarter, compared to analysts' expectations of $2.77 million. Zevra Therapeutics had a negative trailing twelve-month return on equity of 38.58% and a negative net margin of 548.93%.

What ETF holds Zevra Therapeutics' stock ?

iShares Neuroscience and Healthcare ETF holds 3,689 shares of ZVRA stock, representing 0.43% of its portfolio.

What is Zevra Therapeutics' stock symbol?

Zevra Therapeutics trades on the NASDAQ under the ticker symbol "ZVRA."

How do I buy shares of Zevra Therapeutics?

Shares of ZVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zevra Therapeutics' stock price today?

One share of ZVRA stock can currently be purchased for approximately $5.43.

How much money does Zevra Therapeutics make?

Zevra Therapeutics (NASDAQ:ZVRA) has a market capitalization of $187.55 million and generates $10.46 million in revenue each year. The company earns $-41,540,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

How can I contact Zevra Therapeutics?

Zevra Therapeutics' mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The official website for the company is www.kempharm.com. The company can be reached via phone at (321) 939-3416, via email at jrando@tiberend.com, or via fax at 319-665-2577.

This page (NASDAQ:ZVRA) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -